The FDA has cleared Nexstim’s NBT system for the treatment of major depressive disorder.
Your search for major depressive disorder returned 42 results
Click on a filter below to refine your search. Remove a filter to broaden your search.
Screening recommended for those aged 12 to 18, however there is insufficient evidence to assess for children aged 11 and younger.
HIV-infected adults with major depressive disorder have a 30% increased risk for acute myocardial infarction.
The influence of gut microbiota extends to the brain via neuroinflammation, resulting in symptoms associated with major depressive disorder.
Researchers conducted an 8-week, open-label, single-arm study and a subsequent 2-stage, sequential, parallel comparison study to assess the use of pimavanserin among patients with Parkinson disease and major depressive disorder.
Researchers conducted a study to evaluate the validity of, and satisfaction with, the Cognition KIT DSST mobile app in patients with major depressive disorder.
Patients received 40 Hz gamma tACS to provide data on the use of varying stimulation periods.
Investigating whether serial ketamine treatments change functional connectivity between limbic structures and resting-state networks.
There was insufficient evidence to recommend screening in children aged 11 and younger.
The Food and Drug Administration (FDA) has granted Fast Track designation to an investigational intranasal formulation of racemic ketamine for the potential treatment of acute suicidal ideation and behavior in patients with major depressive disorder.
Sixty percent of patients responded to treatment.
Convergent abnormalities were observed in secondary analyses across portions of the amygdala, hippocampus, subgenual cingulate cortex, and putamen.
This study addresses the question of whether prescription opioid medications has a potentially causal role in the risk for depression and anxiety disorder.
The approval was based on the ASPIRE I and II trials that compared the efficacy and safety of esketamine, an N-methyl-D-aspartate receptor antagonist, to placebo in 449 adults with moderate to severe MDD who had active suicidal ideation and intent.
Patients with psychotic depression who experienced an illness relapse while receiving placebo also had a decline in cortical thickness, emphasizing the essential role antipsychotics play in treating disorders where psychosis is present.
Most older adults with preexisting MDD showed resilience in the first two months of the COVID-19 pandemic, but they express concerns about the future.
The study provides strong evidence for the utility of resting-state fMRI measures in predicting the development of attentional or mood disorders in children.
Some nutrient supplements may be beneficial as adjunctive treatment for common mental health condition.
Changes were more pronounced in depressed volunteers.
Lundbeck announced that the FDA has approved a sNDA for Trintellix to include data regarding improved processing speed.
Researchers sought to address the possible link between cognitive or mood symptoms and statins.
Transcranial magnetic stimulation (TMS) uses magnetic fields to stimulate nerve cells in the brain.
Time spent on mobile phones and social media may contribute to the rise in depression.
For patients with comorbid depression and TBI, NILT is effective in bringing remission.
Depression has been linked to elevated markers of inflammation, and aspirin, a nonsteroid, anti-inflammatory medication, can irreversibly inhibit cyclooxygenase-1 and 2.
Researchers performed a double-blind randomized study to investigate the efficacy of tDCS as an augmentation strategy to sertraline in the treatment of vascular depression.
NMDA receptor signaling is increased in patients with depression and reduced in those with schizophrenia.
Symptoms may become more severe as neurological health declines with age.